Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aethlon Medical Inc (AEMD)
NASDAQ:AEMD
Earnings Data
Report Date
Jun 26, 2025TBA Not Confirmed
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.14Last Year’s EPS
-0.87Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 12, 2025
|% Change Since: -13.43%
|Next Earnings Date:Jun 26, 2025
Earnings Call Sentiment|Neutral
The earnings call indicated a balanced outlook for Aethlon Medical, with significant strides in protocol amendments and cost reduction efforts. However, challenges in patient enrollment and an anticipated increase in operating expenses present ongoing hurdles.Company Guidance
During the Aethlon Medical Third Quarter Fiscal 2025 earnings call, the company provided guidance on their financial performance and clinical trial progress. As of December 31, 2024, Aethlon reported a cash balance of approximately $4.8 million. Operating expenses for the quarter decreased by around 50% to $1.8 million compared to the previous year, primarily due to a $1.3 million reduction in payroll and related expenses, a $300,000 decrease in professional fees, and a $200,000 decrease in general and administrative expenses. The company is advancing its oncology trials in Australia and India, with three patients enrolled in the Australian trial so far. The trial aims to enroll nine to 18 patients to assess the safety and feasibility of the Hemopurifier device. Aethlon is also pursuing similar trials in India, with regulatory approval pending. The company's strategic focus on reducing operating expenses while advancing high-impact clinical programs was highlighted as a key part of their strategy moving forward.Successful Protocol Amendment for Oncology Trial
Aethlon Medical successfully amended the protocol for its oncology trial, eliminating the two-month run-in period for patients and broadening eligibility. This amendment aims to improve enrollment speed and reduce screen failures.
Cost Reduction Achievements
Operating expenses decreased by approximately 50% to $1.8 million compared to $3.6 million the previous year, driven by reductions in payroll, professional fees, and general administrative expenses.
Approval and Expansion of Clinical Sites
The amended protocol received approval from the Human Research Ethics Committee and Research Governance Offices, and will be implemented at all three sites, with the third site in Sydney expected to commence patient enrollment soon.
---
AEMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AEMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 12, 2025 | $0.67 | $0.63 | -5.97% |
| Nov 13, 2024 | $0.41 | $0.40 | -2.44% |
| Aug 14, 2024 | $0.38 | $0.32 | -15.79% |
| Jun 27, 2024 | $0.58 | $0.50 | -13.79% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Aethlon Medical Inc (AEMD) report earnings?
Aethlon Medical Inc (AEMD) is schdueled to report earning on Jun 26, 2025, TBA Not Confirmed.
What is Aethlon Medical Inc (AEMD) earnings time?
Aethlon Medical Inc (AEMD) earnings time is at Jun 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AEMD EPS forecast?
AEMD EPS forecast for the fiscal quarter 2025 (Q4) is -0.14.
---